Numerous nucleic acid-based therapeutics, such as pLenti6/BCRPsi shRNA, pGenesil-BCRP/ABCG2-1 siRNA, pGenesil-BCRP/ABCG2-2 siRNA and MRP1-4 siRNA, were explored against drug-resistant cancer and resulted in altered MDR effects by ABC transporter gene silencing and promoted chemotherapeutic sensitivity to cancer cells [44]. This evidence concerns the gene ABCG2 and cancer.